Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam, Amer Assal, Eszter Lázár‐Molnár, et al.
Trends in Molecular Medicine (2014) Vol. 21, Iss. 1, pp. 24-33
Open Access | Times Cited: 746

Showing 1-25 of 746 citing articles:

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 1521
PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li
PubMed (2020) Vol. 10, Iss. 3, pp. 727-742
Closed Access | Times Cited: 1360
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken, E. John Wherry
Trends in Immunology (2015) Vol. 36, Iss. 4, pp. 265-276
Open Access | Times Cited: 990
T-cell exhaustion in the tumor microenvironment
Yuyong Jiang, Yongsheng Li, Bo Zhu
Cell Death and Disease (2015) Vol. 6, Iss. 6, pp. e1792-e1792
Open Access | Times Cited: 894
Mechanisms Controlling PD-L1 Expression in Cancer
Jong‐Ho Cha, Li-Chuan Chan, Chia‐Wei Li, et al.
Molecular Cell (2019) Vol. 76, Iss. 3, pp. 359-370
Open Access | Times Cited: 746
PD-L1 expression in human cancers and its association with clinical outcomes
Jinming Yu, Xin Wang, Feifei Teng, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 5023-5039
Open Access | Times Cited: 691
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce, Marco Greppi, Giovanna Tabellini, et al.
Journal of Allergy and Clinical Immunology (2016) Vol. 139, Iss. 1, pp. 335-346.e3
Open Access | Times Cited: 410
Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
Julien Caldéraro, Benoı̂t Rousseau, Giuliana Amaddeo, et al.
Hepatology (2016) Vol. 64, Iss. 6, pp. 2038-2046
Open Access | Times Cited: 399
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, et al.
Journal of Cellular Physiology (2019) Vol. 234, Iss. 10, pp. 16824-16837
Closed Access | Times Cited: 383
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Weilei Hu, Guosheng Wang, Dongsheng Huang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 361
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Krzysztof M. Zak, P. Grudnik, Katarzyna Guzik, et al.
Oncotarget (2016) Vol. 7, Iss. 21, pp. 30323-30335
Open Access | Times Cited: 355
Manipulating Intratumoral Fenton Chemistry for Enhanced Chemodynamic and Chemodynamic‐Synergized Multimodal Therapy
Yaofeng Zhou, Siyu Fan, Lili Feng, et al.
Advanced Materials (2021) Vol. 33, Iss. 48
Closed Access | Times Cited: 339
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 301
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong, Qian Sun, Xinwei Zhang
Oncotarget (2016) Vol. 8, Iss. 2, pp. 2171-2186
Open Access | Times Cited: 295
Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
Weiqin Jiang, Yinjun He, Wenguang He, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 257
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes, Sean Caenepeel, Lawren C. Wu
Trends in Immunology (2016) Vol. 37, Iss. 7, pp. 462-476
Closed Access | Times Cited: 251
Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma
Tomonori Sasahira, Tadaaki Kirita
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 8, pp. 2413-2413
Open Access | Times Cited: 241
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, et al.
Translational Oncology (2020) Vol. 13, Iss. 3, pp. 100738-100738
Open Access | Times Cited: 234
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Bo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
The Journal of Experimental Medicine (2019) Vol. 216, Iss. 4, pp. 982-1000
Open Access | Times Cited: 213
PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
Xinyi Tu, Bo Qin, Yong Zhang, et al.
Molecular Cell (2019) Vol. 74, Iss. 6, pp. 1215-1226.e4
Open Access | Times Cited: 207
Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma
Qianquan Ma, Wenyong Long, Changsheng Xing, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 199
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Hongwei Lv, Guishuai Lv, Cian Chen, et al.
Cell Metabolism (2020) Vol. 33, Iss. 1, pp. 110-127.e5
Open Access | Times Cited: 196
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung, Dongjun Jeong, Sanghee Ji, et al.
Cancer Research and Treatment (2016) Vol. 49, Iss. 1, pp. 246-254
Open Access | Times Cited: 184
Macrophage targeting in cancer
Martha Lopez‐Yrigoyen, Luca Cassetta, Jeffrey W. Pollard
Annals of the New York Academy of Sciences (2020) Vol. 1499, Iss. 1, pp. 18-41
Open Access | Times Cited: 181
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 178
Page 1 - Next Page

Scroll to top